DMRA Stock Earnings Estimates Decreased by HC Wainwright

Key Points

• HC Wainwright cut its FY2026 loss estimate to $1.73 per share from $1.67, while maintaining a Buy rating and a $45 price target. It forecasts a $1.70-per-share loss for FY2027.
• DMRA reported a quarterly loss of $0.40 per share, narrower than analysts’ expected $0.52 loss.
• Analyst views are mostly positive: MarketBeat reports an average Buy rating and a $46.38 average price target, though one firm rates the stock Sell.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Free Report) - Stock analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of Damora Therapeutics, Inc. Common Stock in a report issued on Thursday, November 5th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.73) per share for the year, down from their previous forecast of ($1.67). HC Wainwright currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock's current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock's Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.42) EPS and FY2027 earnings at ($1.70) EPS.

A number of other equities analysts have also recently issued reports on DMRA. Weiss Ratings reissued a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Guggenheim began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday. They issued a "buy" rating and a $59.00 target price for the company. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a "buy" rating and a $50.00 target price for the company. Wall Street Zen raised Damora Therapeutics, Inc. Common Stock from a "sell" rating to a "hold" rating in a research note on Sunday. Finally, Wedbush reiterated an "outperform" rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $46.38.

Damora Therapeutics, Inc. Common Stock Stock Performance

DMRA opened at $23.70 on Monday. Damora Therapeutics, Inc. Common Stock has a 1-year low of $4.95 and a 1-year high of $38.33. The company has a market cap of $1.47 billion, a P/E ratio of -7.03 and a beta of 1.52. The company has a fifty day moving average price of $22.72 and a two-hundred day moving average price of $25.70.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.12.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In related news, CEO Jennifer Jarrett purchased 12,500 shares of the firm's stock in a transaction that occurred on Friday, September 25th. The stock was acquired at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares of the company's stock, valued at $10,367,875. This represents a 2.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.40% of the company's stock.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of the company. Arizona State Retirement System purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. Squarepoint Ops LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth $303,000. Seven Fleet Capital Management LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $7,398,000. Finally, Braidwell LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $42,146,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock News Summary

Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:

• Positive Sentiment: Wall Street Zen raised its rating on DMRA to “Hold,” an improvement that may modestly bolster sentiment. Article: Damora Therapeutics Stock Bumped Up to Hold by Wall Street Zen
• Neutral Sentiment: Guggenheim initiated coverage, adding analyst attention; the headline does not specify its rating or price target. Article: Guggenheim Initiates Coverage on Damora Therapeutics
• Neutral Sentiment: DMRA crossed above its 50-day moving average, a potentially constructive technical signal, but the article also references an analyst downgrade. The downgrade’s details were not provided. Article: Damora Stock Crosses Above Fifty Day Moving Average After Analyst Downgrade
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including its FY2027 estimate from a loss of $1.59 to $1.70 per share. It retained a “Buy” rating and $45 price target, tempering the negative read-through. MarketBeat coverage of Damora Therapeutics

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.